Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CI Stock Forecast 2025-2026
$264.58
Current Price
$70.68B
Market Cap
Buy 21
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to CI Price Targets
+42.9%
To High Target of $378.00
+25.9%
To Median Target of $333.00
+2.0%
To Low Target of $270.00
CI Price Momentum
+8.3%
1 Week Change
-13.8%
1 Month Change
-17.3%
1 Year Change
-4.2%
Year-to-Date Change
-24.4%
From 52W High of $350.00
+10.5%
From 52W Low of $239.51
📊 TOP ANALYST CALLS
Did CI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cigna is one of their latest high-conviction picks.
Latest CI Stock Price Targets & Analyst Predictions
Based on our analysis of 39 Wall Street analysts, CI has a bullish consensus with a median price target of $333.00 (ranging from $270.00 to $378.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $264.58, the median forecast implies a 25.9% upside. This outlook is supported by 21 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by A.J. Rice at Credit Suisse, suggesting a 2.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CI Analyst Ratings
21
Buy
4
Hold
0
Sell
CI Price Target Range
Low
$270.00
Average
$333.00
High
$378.00
Current: $264.58
Latest CI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 5, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $300.00 |
| Nov 4, 2025 | Goldman Sachs | Scott Fidel | Buy | Maintains | $330.00 |
| Nov 4, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $333.00 |
| Nov 4, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $375.00 |
| Nov 3, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $300.00 |
| Oct 14, 2025 | Goldman Sachs | Scott Fidel | Buy | Initiates | $370.00 |
| Oct 7, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $354.00 |
| Sep 4, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $383.00 |
| Aug 26, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $365.00 |
| Aug 14, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $340.00 |
| Aug 14, 2025 | Baird | Michael Ha | Outperform | Maintains | $374.00 |
| Aug 4, 2025 | Guggenheim | Jason Cassorla | Buy | Maintains | $350.00 |
| Aug 1, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $354.00 |
| Jun 26, 2025 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $371.00 |
| Jun 3, 2025 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $371.00 |
| Jun 2, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $385.00 |
| May 23, 2025 | Guggenheim | Jason Cassorla | Buy | Reiterates | $388.00 |
| May 12, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $405.00 |
| May 6, 2025 | Guggenheim | Jason Cassorla | Buy | Maintains | $388.00 |
| May 5, 2025 | Piper Sandler | Jessica Tassan | Overweight | Maintains | $374.00 |
The Cigna Group (CI) Competitors
The following stocks are similar to Cigna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
The Cigna Group (CI) Financial Data
The Cigna Group has a market capitalization of $70.68B with a P/E ratio of 11.7x. The company generates $268.08B in trailing twelve-month revenue with a 2.3% profit margin.
Revenue growth is +9.5% quarter-over-quarter, while maintaining an operating margin of +4.0% and return on equity of +15.5%.
Valuation Metrics
Market Cap
$70.68B
Enterprise Value
$98.02B
P/E Ratio
11.7x
PEG Ratio
2.6x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
+9.5%
Gross Margin
+8.9%
Operating Margin
+4.0%
Net Margin
+2.3%
EPS Growth
+152.8%
Financial Health
Cash/Price Ratio
+9.8%
Current Ratio
0.8x
Debt/Equity
81.0x
ROE
+15.5%
ROA
+4.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
The Cigna Group (CI) Business Model
About The Cigna Group
What They Do
Provides global health services and insurance coverage.
Business Model
The company operates a comprehensive business model that includes offering medical, dental, disability, life, and accident insurance to both individuals and businesses. It generates revenue primarily through premiums collected from clients and businesses, while also operating in sectors such as pharmacy benefit management and behavioral health, allowing for diversified income streams.
Additional Information
Cigna is recognized for its innovative approach in the health insurance market, focusing on integrating health services to deliver holistic care solutions. Its extensive network within the managed care sector enables it to address the evolving healthcare needs globally, making it a significant player in the industry.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
71,295
CEO
Mr. David Michael Cordani
Country
United States
IPO Year
1982
Website
www.thecignagroup.comThe Cigna Group (CI) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Cigna Q3 Earnings Beat Estimates on Evernorth Health Unit Strength
CI's Q3 earnings and revenues beat estimates as Evernorth Health Services powers growth despite healthcare headwinds.
Oct 30, 2025
By Zacks Equity Research
Analyst Blog
Does UnitedHealth Stock Have More Upside After Q3 Earnings?
UnitedHealth Group's (UNH) stock hasn't received the post-earnings rally that investors may have hoped for, but the medical giant was able to provide subtle signs that its operations are stabilizing.
Oct 29, 2025
By Shaun Pruitt
Stocks in the News
UnitedHealth Q3 Earnings Beat on Rising Commercial Membership
UNH's Q3 earnings beat estimates on solid commercial membership gains and Optum Rx strength, though profits fall sharply on rising medical costs.
Oct 28, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Cigna Group appointed Dr. Amy Flaster as Chief Medical Officer, effective November 1, 2025. Katya Andresen will lead Excellence & Transformation Initiatives.
Why It Matters
Leadership changes can impact company strategy and performance. Dr. Flaster's role may influence Cigna's healthcare initiatives, potentially affecting stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cigna Group exceeded Q3 profit expectations, benefiting from strong performance in its Evernorth health services unit, which includes the pharmacy benefit management business.
Why It Matters
Cigna's profit beat indicates strong performance in its health services, suggesting robust revenue growth and operational efficiency, which can positively influence investor confidence and stock performance.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Cigna Group's shares dropped 17% after the company forecasted declining profit margins in its pharmacy-benefit-services division, despite reporting stronger-than-expected quarterly earnings.
Why It Matters
Cigna's 17% share drop signals declining profit margins in a key division, raising concerns about sector-wide pressures despite strong earnings, impacting investor confidence and future valuations.
Source: Invezz
Market Sentiment:
Negative
Quick Summary
Cigna Group reported increased profit and revenue in Q3, driven by strong performance in its pharmacy-benefit business, Evernorth.
Why It Matters
Cigna's increased profit and revenue signal strong performance, particularly in its pharmacy-benefit sector, indicating potential growth and stability, which can positively influence stock performance.
Source: WSJ
Market Sentiment:
Positive
Quick Summary
Cigna Group will hold its Q3 2025 earnings call on October 30, 2025, at 8:30 AM EDT, featuring key executives and analysts from various financial institutions.
Why It Matters
Cigna's Q3 2025 earnings call provides insights into its financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cigna Group reported nearly $2 billion in net income for Q3, despite facing increasing costs in its health plans.
Why It Matters
Cigna's strong net income amidst rising costs signals effective management and potential resilience, which may boost investor confidence and affect stock performance positively.
Source: Forbes
Market Sentiment:
Positive
Frequently Asked Questions About CI Stock
What is The Cigna Group's (CI) stock forecast for 2026?
Based on our analysis of 39 Wall Street analysts, The Cigna Group (CI) has a median price target of $333.00. The highest price target is $378.00 and the lowest is $270.00.
Is CI stock a good investment in 2026?
According to current analyst ratings, CI has 21 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $264.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CI stock?
Wall Street analysts predict CI stock could reach $333.00 in the next 12 months. This represents a 25.9% increase from the current price of $264.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is The Cigna Group's business model?
The company operates a comprehensive business model that includes offering medical, dental, disability, life, and accident insurance to both individuals and businesses. It generates revenue primarily through premiums collected from clients and businesses, while also operating in sectors such as pharmacy benefit management and behavioral health, allowing for diversified income streams.
What is the highest forecasted price for CI The Cigna Group?
The highest price target for CI is $378.00 from at , which represents a 42.9% increase from the current price of $264.58.
What is the lowest forecasted price for CI The Cigna Group?
The lowest price target for CI is $270.00 from A.J. Rice at Credit Suisse, which represents a 2.0% increase from the current price of $264.58.
What is the overall CI consensus from analysts for The Cigna Group?
The overall analyst consensus for CI is bullish. Out of 39 Wall Street analysts, 21 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $333.00.
How accurate are CI stock price projections?
Stock price projections, including those for The Cigna Group, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 8, 2025 8:31 AM UTC